10 RESULTS
COMMENT Much has been said on aducanumab already and, as in any scientific debate, opinions differ widely. Unfortunately, as was evident from the FDA hearing, the debate has become polarized, as if it were politics. This is never beneficial to any debate. This ...
COMMENT The virtual presentation of the DIAN-TU results at AD/PD was skillfully done and rich in content. The clinical endpoint was negative, as was reported before. Especially striking was the decline in the symptomatic group with CDR>0 equally in all three ...
COMMENT This pandemic is an unparalleled event, which will have a huge impact on research in the long term. The Netherlands is now in almost complete lockdown. Schools, restaurants, shops are all closed, everything except supermarkets, etc. In the hospitals, ...
COMMENT The general message that a noninvasive neurophysiological technique can provide that much relevant information on molecular AD pathophysiology based on just one minute of data is quite baffling, and illustrates the growing relevance of MEG for clinical ...
COMMENT I was disappointed but also not completely surprised. Reasons include the small sample, the late increase in dose, and the unknown test characteristics of the four cognitive tests in this population, especially since some of the participants did not have ...
COMMENT I think that anything that is unproven/not investigated for Alzheimer’s disease should not be used! I never prescribe supplements, but do advise that people follow a healthy lifestyle, including meals that contain all the necessary vitamins. If ...
COMMENT It is very difficult to make comments based on the press release only. Having said that, I was never optimistic about this drug. It has a different isoform as all the others (Ig4 vs Ig1); has little ARIA, which, in my opinion, also indicates less efficacy ...
COMMENT IDEAS is a much-needed study. The main outcome from the perspective of third payers will be health economics. It is likely that with the current pricing of amyloid PET scans and the absence of any specific, approved, anti-amyloid-directed therapy, the ...
COMMENT I applaud the EMA for taking this, and the previous, initiative, since they clearly may boost industry to use these markers in future clinical trials. Further, both EMA guidelines clearly underline the rationale of the concept reflected in the Dubois set ...
COMMENT Age and Atrophy: Nothing to Worry About? In this paper, Burgmans et al. argue that previous studies suggesting that age causes cortical atrophy on MRI may be flawed because they included subjects who, in fact, had preclinical dementia. If true, this would ...
